FDA’s Pazdur Believes ‘Advanced Research’ Project Could Address Trial ‘Wastefulness’
Executive Summary
ARPA-H could be a solution to some of FDA’s long-running complaints about US clinical trial infrastructure, the agency's cancer chief says.
You may also be interested in...
Fluff Or Next Potential Discovery? FDA Wants Simpler Clinical Trials, But Not Telling Sponsors Endpoints Are Unnecessary
Some of the growing number of secondary and tertiary endpoints may not be needed, but also could fuel future products and advance science.
Project Pragmatica: US FDA’s OCE Initiative Aims To Encourage Simple Clinical Trials
OCE Director Richard Pazdur says idea for the latest initiative stemmed from a clinical trial in lung cancer that he thought only needed to measure the impact on overall survival.
NIH Director Collins’ Departure May Revive Patent March-In Debate
Confirmation hearing for successor will present opportunity to press the Biden administration on the patent march-in issue, but a policy change seems unlikely—unless the President feels a strong need to act on drug pricing in the absence of legislation.